evocatal and EUCODIS Bioscience Enter Into Collaboration Agreement
Industrial biotech companies EUCODIS Bioscience and evocatal today announced
the formation of an alliance to jointly market the companies’ industrial
enzyme products, including alcohol dehydrogenases, lipases, and other enzymes.
The two companies will leverage their knowledge of customers’ needs in
their respective markets as well as their complementary resources to provide
existing and future customers with a broader choice of novel enzymes and
Both parties have already started to align their marketing and sales
activities, including their product catalogs, and are representing and
marketing each partner’s products at industry trade fairs, beginning with
Financial terms of the agreement are not being disclosed.
“We are excited about the potential of our alliance with evocatal, who
combine an impressive entrepreneurial spirit with a deep understanding of
developing innovative enzymes for the fine chemicals industry,” said
strong, technology-driven company with a solid portfolio of branded products.
By forming this partnership we truly join our forces allowing the partners to
significantly broaden their offerings to existing and to new customers.”
team up in this process to significantly increase our customers’ benefit.
Customers have now access to a larger enzyme portfolio through a single
channel and also to a much broader service network.”
“We can thus provide more expertise in biocatalysis,” added Dr.
both of us in our continuous striving to provide the best possible service.”
evocatal and EUCODIS Bioscience jointly look forward to a great teamwork
and fruitful cooperation to serve their customers’ needs.
About EUCODIS Bioscience
EUCODIS Bioscience provides enzymes to the chemical, health care, and
other industries, and offers custom-engineering and custom-manufacturing
Customers use EUCODIS Bioscience’ enzymes and services to make their
manufacturing processes more efficient and cleaner and to introduce products
with superior properties. The Company’s technology of in vivo-recombination
is a proven tool for the directed evolution of enzymes that perform to
customers’ specific requirements.
Enzymes are proteins that catalyze highly specific chemical reactions,
offering a safer, cleaner, and competitive alternative to traditional
chemistry. They are at the center of industrial, or “white” biotechnology, a
fast growing industry segment with sales in excess of
Led by an experienced management team, EUCODIS Bioscience is backed by
Austrian and German institutional venture capital funds, founders, and
private investors. The Company is headquartered in
For more information, please visit http://www.eucodisbioscience.com
evocatal GmbH is a
in the development of biocatalysts and enzyme-based chemical processes.
The name evocatal connects the terms ‘evolution’ and ‘catalysis’ and
stands for the core competencies of the Company: the tailor-made development
of new enzymes for use in the production of complex low-molecular weight
compounds and fine chemicals for the pharmaceutical industry.
evocatal has built up a portfolio of proprietary biocatalysts
(evozymes(R)) that is continuously broadened by innovative new developments
meeting the demands in industry. The company furthermore offers the
development of enzymes and enzyme production systems as contract service.
Furthermore evocatal has commercialized the first fluorescent protein for
anaerobic applications in biomedical research and development.
For more information, please visit http://www.evocatal.com Company contact EUCODIS Bioscience: Thomas Fischer, MBA CEO EUCODIS Bioscience Campus Vienna Biocenter II Viehmarktgasse 2 a/ 2 OG A-1030 Vienna AUSTRIA +43-1-8900804 firstname.lastname@example.org Media contact EUCODIS Bioscience: Frank Butschbacher Investor Relations & Communications http://www.butschbacher.net +43-650-7844940 email@example.com Company contact evocatal: Dr. Thorsten Eggert CEO evocatal GmbH Merowingerplatz 1a 40225 Duesseldorf GERMANY +49-211-1576095-0 firstname.lastname@example.org
SOURCE EUCODIS Bioscience